Form D · Pharmaceuticals
AltrixBio, Inc.
Lowell, MA · CIK 0002040517
Offering snapshot reported Jun 16, 2025 · SEC filing
- Reported sold
- $1.15M Offering amount: $10M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Apr 30, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2025 | Initial | $1,150,015 | No comparison | 20 | SEC filing |
| Jun 13, 2025 | Initial | $1,150,015 | No comparison | 20 | SEC filing |
| Jun 13, 2025 | Amendment | $6,632,847 | $5,482,832vs Jun 13, 2025 | 50 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 04, 06c, 4a5
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $250K (estimated)
- Form D file number
- 021-548979
Source: Form D, filed Jun 16, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nancy Briefs | Director, Executive |
| John Brooks | Director |
| Jeffrey Karp | Director |
| Ali Tavakkoli | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
110 Canal Street 4th Floor
Lowell, MA, 01852
Phone: 302-658-7581
Lowell, MA, 01852
Phone: 302-658-7581